Henry Schein
HSIC
83.52
-1.28
-1.51%
Henry Schein
US · HSIC
#1526 by market cap
Listed 1970
83.52
-1.28
-1.51%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
Recent news
-
Rating change
Analysts Conflicted on These Healthcare Names: Henry Schein (HSIC), Arcus Biosciences (RCUS) and Incyte (INCY)TipRanks · 2026/10/21
-
Rating change
Henry Schein Price Target Raised to $95.00/Share From $94.00 by UBSDow Jones · 2026/11/5
-
Company notice
Henry Schein | 3: Initial statement of beneficial ownership of securities- Caprais EmmanuelSEC · 2026/11/7
-
Company notice
Henry Schein | SCHEDULE 13G/A: OthersSEC · 2026/11/12
-
Rating change
Barrington Maintains Henry Schein(HSIC.US) With Buy Rating, Maintains Target Price $104Market Newswire · 2026/10/21
-
A Quick Look at Today's Ratings for Henry Schein(HSIC.US), With a Forecast Between $85 to $110Market Newswire · 2026/11/5
-
Rating change
Leerink Partners Maintains Henry Schein(HSIC.US) With Hold Rating, Announces Target Price $92Market Newswire · 2026/10/14
-
Rating change
Baird Adjusts Henry Schein Price Target to $107 From $109MT Newswires · 2026/10/15
-
Rating change
Henry Schein Price Target Cut to $100.00/Share From $105.00 by Evercore ISI GroupDow Jones · 2026/11/4
-
Company notice
Henry Schein | 10-Q: Quarterly reportSEC · 2026/11/4
-
Evercore ISI Group Maintains Outperform on Henry Schein, Lowers Price Target to $100Benzinga · 2026/11/4
-
Here's What Analysts Are Forecasting For Henry Schein, Inc. (NASDAQ:HSIC) After Its Third-Quarter ResultsSimply Wall St · 2026/11/6
-
Rating change
Henry Schein Price Target Cut to $92.00/Share From $96.00 by Leerink PartnersDow Jones · 2026/10/15
-
Rating change
Henry Schein Is Maintained at Neutral by UBSDow Jones · 2026/11/5
-
Rating change
Henry Schein Is Maintained at Outperform by Evercore ISI GroupDow Jones · 2026/11/4
-
Company notice
Henry Schein | 8-K: Current reportSEC · 2026/11/3
-
UBS Adjusts Henry Schein Price Target to $95 From $94, Maintains Neutral RatingMT Newswires · 2026/11/4
-
Barclays Maintains Henry Schein(HSIC.US) With Buy Rating, Maintains Target Price $100Market Newswire · 2026/11/4
-
Company notice
Henry Schein | 8-K: Current reportSEC · 2026/10/8
-
Rating change
Henry Schein Is Maintained at Market Perform by Leerink PartnersDow Jones · 2026/10/15
-
Rating change
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Pharvaris (PHVS) and Tenet Healthcare (THC)TipRanks · 2026/10/12
-
Company notice
Henry Schein | 8-K: Current reportSEC · 2026/9/22
-
Company notice
Henry Schein | 4: Statement of changes in beneficial ownership of securities-Officer Albertini AndreaSEC · 2026/9/10
-
Rating change
Morgan Stanley Maintains Henry Schein(HSIC.US) With Sell Rating, Maintains Target Price $64Market Newswire · 2026/10/12
-
Company notice
Henry Schein | SCHEDULE 13G: OthersSEC · 2026/8/6
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:01:08 · For reference only, not investment advice and not tailored to your situation.
Henry Schein discussion 0 comments